Calreticulin – a multifaced protein
References
- Alaiya A., Roblick U., Egevad L., Carlsson A., Franzén B., Volz D., Huwendiek S., Linder S., Auer G.: Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal. Cell. Pathol., 2000; 21: 1–9
- Alfonso P., Núñez A., Madoz-Gurpide J., Lombardia L., Sánchez L., Casal J.I.: Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics, 2005; 5: 2602–2611
- Araki M., Yang Y., Masubuchi N., Hironaka Y., Takei H., Morishita S., Mizukami Y., Kan S., Shirane S., Edahiro Y., Sunami Y., Ohsaka A., Komatsu N.: Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood, 2016; 127: 1307–1316
- Arshad N., Cresswell P.: Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I. J. Biol. Chem., 2018; 293: 9555–9569
- Chachoua I., Pecquet C., El-Khoury M., Nivarthi H., Albu R.I., Marty C., Gryshkova V., Defour J.P., Vertenoeil G., Ngo A., Koay A., Raslova H., Courtoy P.J., Choong M.L., Plo I., et al.: Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood, 2016; 127: 1325–1335
- Chahed K., Kabbage M., Ehret-Sabatier L., Lemaitre-Guillier C., Remadi S., Hoebeke J., Chouchane L.: Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: The two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses. Int. J. Oncol., 2005; 27: 1425–1431
- Chang H.H., Lee H., Hu M.K., Tsao P.N., Juan H.F., Huang M.C., Shih Y.Y., Wang B.J., Jeng Y.M., Chang C.L., Huang S.F., Tsay Y.G., Hsieh F.J., Lin K.H., Hsu W.M., et al.: Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma. Clin. Cancer Res., 2010; 16: 4411–4420
- Chao M.P., Jaiswal S., Weissman-Tsukamoto R., Alizadeh A.A., Gentles A.J., Volkmer J., Weiskopf K., Willingham S.B., Raveh T., Park C.Y., Majeti R., Weissman I.L.: Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counter-balanced by CD47. Sci. Transl. Med., 2010; 2: 63ra94
- Chiang W.F., Hwang T.Z., Hour T.C., Wang L.H., Chiu C.C., Chen H.R., Wu Y.J., Wang C.C., Wang L.F., Chien C.Y., Chen J.H., Hsu C.T., Chen J.Y.F.: Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma. Oral Oncol., 2013; 49: 534–541
- Cid N.D., Jeffery E., Rizvi S.M., Stamper E., Peters L.R., Brown W.C., Provoda C., Raghavan M.: Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathway. J. Biol. Chem., 2010; 285: 4520–4535
- Cockram T.O.J., Puigdellívol M., Brown G.C.: Calreticulin and galectin-3 opsonise bacteria for phagocytosis by microglia. Front. Immunol., 2019; 10: 2647
- Coppolino M.G., Woodside M.J., Demaurex N., Grinstein S., St-Arnaud R., Dedhar S.: Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature, 1997; 386: 843–847
- Cordua S., Kjaer L., Skov V., Pallisgaard N., Hasselbalch H.C., Ellervik C.: Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood, 2019; 134: 469–479
- Di Martino S., Crescente G., De Lucia V., Di Paolo M., Marotta G., De Lucia D., Abbadessa A.: The emerging role of calreticulin in cancer cells. World Cancer Res. J., 2017; 4: e926
- Du X.L., Hu H., Lin D.C., Xia S.H., Shen X.M., Zhang Y., Luo M.L., Feng Y.B., Cai Y., Xu X., Han Y.L., Zhan Q.M., Wang M.R.: Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J. Mol. Med., 2007; 85: 863–875
- Eder-Azanza L., Navarro D., Aranaz P., Novo F.J., Cross N.C., Vizmanos J.L.: Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling. Leukemia, 2014; 28: 2106–2109
- Eggleton P., Bremer E., Dudek E., Michalak M.: Calreticulin, a therapeutic target? Expert Opin. Ther. Targets, 2016; 20: 1137–1147
- Elf S., Abdelfattah N.S., Chen E., Perales-Patón J., Rosen E.A., Ko A., Peisker F., Florescu N., Giannini S., Wolach O., Morgan E.A., Tothova Z., Losman J.A., Schneider R.K., Al-Shahrour F., et al.: Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov., 2016; 6: 368–381
- Falchi M., Varricchio L., Martelli F., Marra M., Picconi O., Tafuri A., Girelli G., Uversky V.N., Migliaccio A.R.: The calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Exp. Hematol., 2017; 50: 53–76
- Fucikova J., Becht E., Iribarren K., Goc J., Remark R., Damotte D., Alifano M., Devi P., Biton J., Germain C., Lupo A., Fridman W.H., Dieu-Nosjean M.C., Kroemer G., Sautès-Fridman C., et al.: Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res., 2016; 76: 1746–1756
- Fucikova J., Kline J.P., Galluzzi L., Spisek R.: Calreticulin arms NK cells against leukemia. Oncoimmunology, 2020; 9: 1671763
- Fucikova J., Moserova I., Urbanova L., Bezu L., Kepp O., Cremer I., Salek C., Strnad P., Kroemer G., Galluzzi L., Spisek R.: Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front. Immunol., 2015; 6: 402
- Fucikova J., Truxova I., Hensler M., Becht E., Kasikova L., Moserova I., Vosahlikova S., Klouckova J., Church S.E., Cremer I., Kepp O., Kroemer G., Galluzzi L., Salek C., Spisek R.: Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood, 2016; 128: 3113–3124
- Galluzzi L., Buqué A., Kepp O., Zitvogel L., Kroemer G.: Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol., 2017; 17: 97–111
- Guo L., Nakamura K., Lynch J., Opas M., Olson E.N., Agellon L.B., Michalak M.: Cardiac-specific expression of calcineurin reverses embryonic lethality in calreticulin-deficient mouse. J. Biol. Chem., 2002; 277: 50776–50779
- Han A., Li C., Zahed T., Wong M., Smith I., Hoedel K., Green D., Boiko A.D.: Calreticulin is a critical cell survival factor in malignant neoplasms. PLoS Biol., 2019; 17: e3000402
- Han L., Schubert C., Köhler J., Schemionek M., Isfort S., Brümmendorf T.H., Koschmieder S., Chatain N.: Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J. Hematol. Oncol., 2016; 9: 45
- Hellman K., Alaiya A.A., Schedvins K., Steinberg W., Hellström A.C., Auer G.: Protein expression patterns in primary carcinoma of the vagina. Br. J. Cancer, 2004; 91: 319–326
- Holmström M.O., Cordua S., Skov V., Kjær L., Pallisgaard N., Ellervik C., Hasselbalch H.C., Andersen M.H.: Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. Cancer Immunol. Immunother., 2020; 69: 315–324
- Holmström M.O., Martinenaite E., Ahmad S.M., Met Ö., Friese C., Kjær L., Riley C.H., Thor Straten P., Svane I.M., Hasselbalch H.C., Andersen M.H.: The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia, 2018; 32: 429–437
- How J., Hobbs G.S., Mullally A.: Mutant calreticulin in myeloproliferative neoplasms. Blood, 2019; 134: 2242–2248
- Hsu W.M., Hsieh F.J., Jeng Y.M., Kuo M.L., Chen C.N., Lai D.M., Hsieh L.J., Wang B.T., Tsao P.N., Lee H., Lin M.T., Lai H.S., Chen W.J.: Calreticulin expression in neuroblastoma - a novel independent prognostic factor. Ann. Oncol., 2005; 16: 314–321
- Jo S.H., Choi J.A., Lim Y.J., Lee J., Cho S.N., Oh S.M., Go D., Kim S.H., Song C.H.: Calreticulin modulates the intracellular survival of mycobacteria by regulating ER-stress-mediated apoptosis. Onco-target, 2017; 8: 58686–58698
- Kageyama S., Isono T., Matsuda S., Ushio Y., Satomura S., Terai A., Arai Y., Kawakita M., Okada Y., Yoshiki T.: Urinary calreticulin in the diagnosis of bladder urothelial carcinoma. Int. J. Urol., 2009; 16: 481–486
- Kasikova L., Hensler M., Truxova I., Skapa P., Laco J., Belicova L., Praznovec I., Vosahlikova S., Halaska M.J., Brtnicky T., Rob L., Presl J., Kostun J., Cremer I., Ryska A., et al.: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. J. Immunother. Cancer, 2019; 7: 312
- Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., Them N.C., Berg T., Gisslinger B., Pietra D., Chen D., Vladimer G.I., Bagienski K., Milanesi C., Casetti I.C., et al.: Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med., 2013; 369: 2379–2390
- Limjindaporn T., Wongwiwat W., Noisakran S., Srisawat C., Netsawang J., Puttikhunt C., Kasinrerk W., Avirutnan P., Thiemmeca S., Sriburi R., Sittisombut N., Malasit P., Yenchitsomanus P.: Interaction of dengue virus envelope protein with endoplasmic reticulum-resident chaperones facilitates dengue virus production. Biochem. Biophys. Res. Commun., 2009; 379: 196–200
- Liu P., Zhao L., Kroemer G., Kepp O.: Secreted calreticulin mutants subvert anticancer immunosurveillance. OncoImmunology, 2019; 9: 1708126
- Liu P., Zhao L., Loos F., Marty C., Xie W., Martins I., Lachkar S., Qu B., Waeckel-Énée E., Plo I., Vainchenker W., Perez F., Rodriguez D., López-Otin C., van Endert P., et al.: Immunosuppression by mutated calreticulin released from malignant cells. Mol. Cell, 2020; 77: 748–760.e9
- Lu Y.C., Weng W.C., Lee H.: Functional roles of calreticulin in cancer biology. Biomed. Res. Int., 2015; 2015: 526524
- Lwin Z.M., Guo C., Salim A., Yip G.W., Chew F.T., Nan J., Thike A.A., Tan P.H., Bay B.H.: Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod. Pathol., 2010; 23: 1559–1566
- Lynch J., Guo L., Gelebart P., Chilibeck K., Xu J., Molkentin J.D., Agellon L.B., Michalak M.: Calreticulin signals upstream of calcineurin and MEF2C in a critical Ca2+-dependent signaling cascade. J. Cell Biol., 2005; 170: 37–47
- Margolin E., Oh Y.J., Verbeek M., Naude J., Ponndorf D., Mesh-cheriakova Y.A., Peyret H., van Diepen M.T., Chapman R., Meyers A.E., Lomonossoff G.P., Matoba N., Williamson A.L., Rybicki E.P.: Co-expression of human calreticulin significantly improves the production of HIV gp140 and other viral glycoproteins in plants. Plant Biotechnol. J., 2020; 18: 2109–2117
- Marty C., Pecquet C., Nivarthi H., El-Khoury M., Chachoua I., Tulliez M., Villeval J.L., Raslova H., Kralovics R., Constantinescu S.N., Plo I., Vainchenker W.: Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood, 2016; 127: 1317–1324
- Mesaeli N., Nakamura K., Zvaritch E., Dickie P., Dziak E., Krause K.H., Opas M., MacLennan D.H., Michalak M.: Calreticulin is essential for cardiac development. J. Cell Biol., 1999; 144: 857–868
- Michalak M., Groenendyk J., Szabo E., Gold L.I., Opas M.: Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem. J., 2009; 417: 651–666
- Migliaccio A.R., Uversky V.N.: Dissecting physical structure of calreticulin, an intrinsically disordered Ca2+-buffering chaperone from endoplasmic reticulum. J. Biomol. Struct. Dyn., 2018; 36: 1617–1636
- Nakamura K., Zuppini A., Arnaudeau S., Lynch J., Ahsan I., Krause R., Papp S., De Smedt H., Parys J.B., Muller-Esterl W., Lew D.P., Krause K.H., Demaurex N., Opas M., Michalak M.: Functional specialization of calreticulin domains. J. Cell Biol., 2001; 154: 961–972
- Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., Avezov E., Li J., Kollmann K., Kent D.G., Aziz A., Godfrey A.L., Hinton J., Martincorena I., Van Loo P., et al.: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med., 2013; 369: 2391–2405
- Nguyen T.O., Capra J.D., Sontheimer R.D.: Calreticulin is transcriptionally upregulated by heat shock, calcium and heavy metals. Mol. Immunol., 1996; 33: 379–386
- Ostwald T.J., MacLennan D.H.: Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum. J. Biol. Chem., 1974; 249: 974–979
- Païdassi H., Tacnet-Delorme P., Verneret M., Gaboriaud C., Houen G., Duus K., Ling W.L., Arlaud G.J., Frachet P.: Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition. J. Mol. Biol., 2011; 408: 277–290
- Papp S., Fadel M.P., Kim H., McCulloch C.A., Opas M.: Calreticulin affects fibronectin-based cell-substratum adhesion via the regulation of c-Src activity. J. Biol. Chem., 2007; 282: 16585–16598
- Park S., Huh H.J., Mun Y.C., Seong C.M., Chung W.S., Chung H.S., Huh J.: Calreticulin mRNA expression and clinicopathological characteristics in acute myeloid leukemia. Cancer Genet., 2015; 208: 630–635
- Peng R.Q., Chen Y.B., Ding Y., Zhang R., Zhang X., Yu X.J., Zhou Z.W., Zeng Y.X., Zhang X.S.: Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J. Gastroenterol., 2010; 16: 2428–2434
- Pietra D., Rumi E., Ferretti V.V., Di Buduo C.A., Milanesi C., Cavalloni C., Sant’Antonio E., Abbonante V., Moccia F., Casetti I.C., Bellini M., Renna M.C., Roncoroni E., Fugazza E., Astori C., et al.: Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia, 2016; 30: 431–438
- Qiu Y., Lynch J., Guo L., Yatsula B., Perkins A.S., Michalak M.: Regulation of the calreticulin gene by GATA6 and Evi-1 transcription factors. Biochemistry, 2008; 47: 3697–3704
- Saito Y., Ihara Y., Leach M.R., Cohen-Doyle M.F., Williams D.B.: Calreticulin functions in vitro as a molecular chaperone for both glycosylated and non-glycosylated proteins. EMBO J., 1999; 18: 6718–6729
- Schcolnik-Cabrera A., Oldak B., Juárez M., Cruz-Rivera M., Flisser A., Mendlovic F.: Calreticulin in phagocytosis and cancer: Opposite roles in immune response outcomes. Apoptosis, 2019; 24: 245–255
- Sheng W., Chen C., Dong M., Zhou J., Liu Q., Dong Q., Li F.: Over-expression of calreticulin contributes to the development and progression of pancreatic cancer. J. Cell. Physiol., 2014; 229: 887–897
- Shide K., Kameda T., Yamaji T., Sekine M., Inada N., Kamiunten A., Akizuki K., Nakamura K., Hidaka T., Kubuki Y., Shimoda H., Kitanaka A., Honda A., Sawaguchi A., Abe H., et al.: Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia, 2017; 31: 1136–1144
- Shivarov V., Ivanova M., Tiu R.V.: Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca2+: Some mechanistic and therapeutic implications. Blood Cancer J., 2014; 4: e185
- Stanley R.F., Steidl U.: Molecular mechanism of mutant CALR-mediated transformation. Cancer Discov., 2016; 6: 344–346
- Szuber N., Lamontagne B., Busque L.: Novel germline mutations in the calreticulin gene: Implications for the diagnosis of myeloproliferative neoplasms. J. Clin. Pathol., 2016; 69: 1033–1036
- Tefferi A., Wassie E.A., Guglielmelli P., Gangat N., Belachew A.A., Lasho T.L., Finke C., Ketterling R.P., Hanson C.A., Pardanani A., Wolanskyj A.P., Maffioli M., Casalone R., Pacilli A., Vannucchi A.M., et al.: Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am. J. Hematol., 2014; 89: E121–E124
- Truxova I., Kasikova L., Salek C., Hensler M., Lysak D., Holicek P., Bilkova P., Holubova M., Chen X., Mikyskova R., Reinis M., Kovar M., Tomalova B., Kline J.P., Galluzzi L., et al.: Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica, 2020; 105: 1868–1878
- Vainchenker W., Kralovics R.: Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood, 2017; 129: 667–679
- Vaksman O., Davidson B., Tropé C., Reich R.: Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum. Pathol., 2013; 44: 2677–2683
- Varricchio L., Falchi M., Dall’Ora M., De Benedittis C., Ruggeri A., Uversky V.N., Migliaccio A.R.: Calreticulin: Challenges posed by the intrinsically disordered nature of calreticulin to the study of its function. Front. Cell Dev. Biol., 2017; 5: 96
- Wijeyesakere S.J., Bedi S.K., Huynh D., Raghavan M.: The C-terminal acidic region of calreticulin mediates phosphatidylserine binding and apoptotic cell phagocytosis. J. Immunol., 2016; 196: 3896–3909
- Wijeyesakere S.J., Gagnon J.K., Arora K., Brooks C.L.3rd, Raghavan M.: Regulation of calreticulin-major histocompatibility complex (MHC) class I interactions by ATP. Proc. Natl. Acad. Sci. USA, 2015; 112: E5608–E5617
- Yue X., Wang H., Zhao F., Liu S., Wu J., Ren W., Zhu Y.: Hepatitis B virus-induced calreticulin protein is involved in IFN resistance. J. Immunol., 2012; 189: 279–286
- Zamanian M., Veerakumarasivam A., Abdullah S., Rosli R.: Calreticulin and cancer. Pathol. Oncol. Res., 2013; 19: 149–154
DOI: https://doi.org/10.5604/01.3001.0014.8892 | Journal eISSN: 1732-2693
Language: English
Page range: 328 - 336
Submitted on: Jul 2, 2020
Accepted on: Nov 24, 2020
Published on: May 18, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Related subjects:
© 2021 Zuzanna Kanduła, Krzysztof Lewandowski, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.